دورية أكاديمية
أعرض في EDS

Chelators in the treatment of iron accumulation in Parkinson's disease.

التفاصيل البيبلوغرافية
العنوان: Chelators in the treatment of iron accumulation in Parkinson's disease.
المؤلفون: Mounsey RB; School of Medical Sciences, College of Life Sciences and Medicine Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK., Teismann P
المصدر: International journal of cell biology [Int J Cell Biol] 2012; Vol. 2012, pp. 983245. Date of Electronic Publication: 2012 Jun 13.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Hindawi Pub. Corp Country of Publication: United States NLM ID: 101517861 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1687-8884 (Electronic) Linking ISSN: 16878876 NLM ISO Abbreviation: Int J Cell Biol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: New York, NY : Hindawi Pub. Corp.
مستخلص: Iron is an essential element in the metabolism of all cells. Elevated levels of the metal have been found in the brains of patients of numerous neurodegenerative disorders, including Parkinson's disease (PD). The pathogenesis of PD is largely unknown, although it is thought through studies with experimental models that oxidative stress and dysfunction of brain iron homeostasis, usually a tightly regulated process, play significant roles in the death of dopaminergic neurons. Accumulation of iron is present at affected neurons and associated microglia in the substantia nigra of PD patients. This additional free-iron has the capacity to generate reactive oxygen species, promote the aggregation of α-synuclein protein, and exacerbate or even cause neurodegeneration. There are various treatments aimed at reversing this pathologic increase in iron content, comprising both synthetic and natural iron chelators. These include established drugs, which have been used to treat other disorders related to iron accumulation. This paper will discuss how iron dysregulation occurs and the link between increased iron and oxidative stress in PD, including the mechanism by which these processes lead to cell death, before assessing the current pharmacotherapies aimed at restoring normal iron redox and new chelation strategies undergoing research.
References: Br J Pharmacol. 2005 Dec;146(8):1041-59. (PMID: 16205720)
Acta Neuropathol. 2000 Aug;100(2):111-4. (PMID: 10963356)
J Neural Transm (Vienna). 2011 Feb;118(2):223-31. (PMID: 21165659)
Mov Disord. 2008 Apr 30;23(6):904-7. (PMID: 18383118)
J Neural Transm (Vienna). 1997;104(4-5):469-81. (PMID: 9295179)
Parkinsonism Relat Disord. 2011 Jul;17(6):423-30. (PMID: 21550835)
J Neural Transm Suppl. 2006;(70):133-42. (PMID: 17017520)
Expert Rev Neurother. 2003 Nov;3(6):737-49. (PMID: 19810877)
Neuropathol Appl Neurobiol. 1994 Oct;20(5):468-72. (PMID: 7845532)
J Neural Transm. 1988;74(3):199-205. (PMID: 3210014)
Mov Disord. 2011 Aug 1;26(9):1756-9. (PMID: 21557313)
Brain Res Bull. 2009 Dec 16;80(6):397-402. (PMID: 19712727)
Biochem Pharmacol. 1989 Dec 1;38(23):4177-82. (PMID: 2512934)
Drug Metab Dispos. 2003 May;31(5):572-9. (PMID: 12695345)
J Neurol Neurosurg Psychiatry. 1998 Nov;65(5):781-4. (PMID: 9810958)
Lancet Neurol. 2006 Jun;5(6):525-35. (PMID: 16713924)
Ann N Y Acad Sci. 2003 Jun;991:189-98. (PMID: 12846987)
J Neurochem. 2001 Mar;76(6):1766-73. (PMID: 11259494)
Int J Biochem Cell Biol. 1999 Oct;31(10):1139-52. (PMID: 10582343)
Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2696-701. (PMID: 8610103)
FASEB J. 2007 Dec;21(14):3835-44. (PMID: 17690154)
Parkinsons Dis. 2010 Dec 26;2011:617472. (PMID: 21234411)
Parkinsons Dis. 2011 Feb 07;2011:431068. (PMID: 21331377)
Brain Res. 2003 Jul 18;978(1-2):241-4. (PMID: 12834920)
J Neurochem. 1989 Feb;52(2):381-9. (PMID: 2911023)
Med Res Rev. 2002 Jan;22(1):26-64. (PMID: 11746175)
Drugs Aging. 1999 Feb;14(2):115-40. (PMID: 10084365)
Neurosignals. 2005;14(1-2):46-60. (PMID: 15956814)
Hum Mol Genet. 2008 Aug 1;17(15):2265-73. (PMID: 18424449)
Toxicology. 2008 Mar 12;245(1-2):101-8. (PMID: 18255213)
J Neurochem. 2005 Oct;95(1):79-88. (PMID: 16181414)
J Biol Chem. 1999 Oct 8;274(41):28849-52. (PMID: 10506125)
Nat Med. 2002 Jun;8(6):600-6. (PMID: 12042811)
NeuroRx. 2005 Jul;2(3):484-94. (PMID: 16389312)
J Neurochem. 1995 Aug;65(2):717-24. (PMID: 7616228)
J Neurochem. 1997 Feb;68(2):732-8. (PMID: 9003064)
Ann N Y Acad Sci. 2004 Mar;1012:306-25. (PMID: 15105275)
J Neural Transm (Vienna). 2006 May;113(5):633-44. (PMID: 16362626)
Biochem Pharmacol. 1997 Nov 1;54(9):973-8. (PMID: 9374417)
Eur J Pharmacol. 1996 Jul 18;308(2):219-25. (PMID: 8840135)
Br Med J (Clin Res Ed). 1985 Aug 17;291(6493):448. (PMID: 3926233)
Cell. 2004 Apr 30;117(3):285-97. (PMID: 15109490)
Nature. 1997 Aug 28;388(6645):839-40. (PMID: 9278044)
Nat Genet. 2001 Aug;28(4):350-4. (PMID: 11438811)
Neurobiol Dis. 2010 Feb;37(2):307-13. (PMID: 19818853)
Ann N Y Acad Sci. 2004 Mar;1012:193-208. (PMID: 15105267)
J Neurochem. 2001 Sep;78(5):1073-82. (PMID: 11553681)
Ageing Res Rev. 2004 Jul;3(3):327-43. (PMID: 15231240)
J Neural Transm (Vienna). 1997;104(6-7):649-60. (PMID: 9444565)
J Neurochem. 2011 Sep;118(6):939-57. (PMID: 21138437)
J Neurosci. 2000 Aug 15;20(16):6048-54. (PMID: 10934254)
J Mol Neurosci. 2004;24(3):401-16. (PMID: 15655262)
Ann N Y Acad Sci. 2004 Mar;1012:1-13. (PMID: 15105251)
Ann Neurol. 1997 Mar;41(3):404-7. (PMID: 9066364)
J Neurosci Res. 1993 May 1;35(1):67-82. (PMID: 7685399)
Neuron. 2001 Jun;30(3):665-76. (PMID: 11430801)
Biochim Biophys Acta. 1996 Jul 31;1275(3):161-203. (PMID: 8695634)
J Biol Chem. 2001 Nov 23;276(47):44284-96. (PMID: 11553618)
Lancet. 1987 Nov 21;2(8569):1219-20. (PMID: 2890848)
J Neural Transm Suppl. 2000;(58):83-96. (PMID: 11128615)
Bioorg Med Chem. 2005 Feb 1;13(3):773-83. (PMID: 15653345)
Neurochem Int. 2006 Nov;49(6):605-9. (PMID: 16806586)
J Neurochem. 1998 Jun;70(6):2492-9. (PMID: 9603214)
J Neurochem. 2003 Sep;86(5):1142-8. (PMID: 12911622)
Am J Clin Nutr. 2001 Oct;74(4):418-25. (PMID: 11566638)
J Neural Transm Suppl. 1995;46:175-82. (PMID: 8821053)
J Cell Sci. 2000 Feb;113 ( Pt 4):635-41. (PMID: 10652256)
Biochem Biophys Res Commun. 2005 Jul 29;333(2):544-9. (PMID: 15950935)
J Neurochem. 1991 Apr;56(4):1441-4. (PMID: 1900527)
Curr Med Chem. 2003 Jun;10(12):1077-84. (PMID: 12678678)
Nat Rev Neurosci. 2004 Nov;5(11):863-73. (PMID: 15496864)
Ann Neurol. 1994 Sep;36(3):348-55. (PMID: 8080242)
Brain Res. 1997 Feb 21;749(1):170-4. (PMID: 9070646)
Curr Opin Chem Biol. 1999 Apr;3(2):200-6. (PMID: 10226041)
Neuropharmacology. 2004 Feb;46(2):254-63. (PMID: 14680763)
Int J Immunopathol Pharmacol. 2005 Jan-Mar;18(1):7-14. (PMID: 15698506)
J Neurochem. 2005 Oct;95(1):68-78. (PMID: 16181413)
J Neurochem. 2001 Apr;77(1):146-56. (PMID: 11279270)
Free Radic Biol Med. 2002 Aug 15;33(4):457-63. (PMID: 12160928)
Blood. 2007 Jul 1;110(1):401-8. (PMID: 17379741)
J Biol Chem. 1996 Dec 27;271(52):33352-7. (PMID: 8969195)
Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18578-83. (PMID: 19011085)
Life Sci. 1997;61(4):343-54. (PMID: 9244360)
Mov Disord. 1993;8(1):1-12. (PMID: 8419792)
J Neural Transm Suppl. 1999;55:57-70. (PMID: 10335493)
Neurosci Lett. 1982 Dec 13;33(3):305-10. (PMID: 7162692)
Ann N Y Acad Sci. 1994 Nov 17;738:201-13. (PMID: 7832429)
J Neurol Sci. 2000 Feb 1;173(1):40-4. (PMID: 10675578)
Blood. 1997 Feb 1;89(3):739-61. (PMID: 9028304)
J Neurochem. 1958 Oct;3(1):41-51. (PMID: 13611557)
J Neurochem. 1988 Jan;50(1):202-8. (PMID: 2891784)
J Neural Transm (Vienna). 2007 Feb;114(2):205-9. (PMID: 16736232)
Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7531-6. (PMID: 9207126)
Neuron. 2003 Mar 27;37(6):899-909. (PMID: 12670420)
Neuron. 2003 Sep 11;39(6):889-909. (PMID: 12971891)
Ann N Y Acad Sci. 1999;890:7-25. (PMID: 10668410)
J Neurochem. 2001 Oct;79(2):225-36. (PMID: 11677250)
Ann Neurol. 1998 Sep;44(3 Suppl 1):S72-84. (PMID: 9749577)
J Neurochem. 1999 Apr;72(4):1617-24. (PMID: 10098869)
Neurology. 1990 Oct;40(10 Suppl 3):suppl 32-7; discussion 37-9. (PMID: 2215972)
Neurodegener Dis. 2010;7(4):219-31. (PMID: 20197647)
Neurology. 1997 Mar;48(3):650-8. (PMID: 9065542)
Nat Neurosci. 2000 Dec;3(12):1301-6. (PMID: 11100151)
Dev Neurosci. 2002;24(2-3):143-53. (PMID: 12401952)
تواريخ الأحداث: Date Created: 20120704 Date Completed: 20120823 Latest Revision: 20240525
رمز التحديث: 20240525
مُعرف محوري في PubMed: PMC3382398
DOI: 10.1155/2012/983245
PMID: 22754573
قاعدة البيانات: MEDLINE
الوصف
تدمد:1687-8884
DOI:10.1155/2012/983245